The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / HSCT for Severe Autoimmune Diseases

HSCT for Severe Autoimmune Diseases

August 14, 2017 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Currently, multiple sclerosis, Crohn’s disease and systemic sclerosis are the autoimmune diseases with the most supporting clinical data, including information from large series and randomized controlled trials. Retrospective analyses support its possible efficacy for additional conditions.6 Currently, no official U.S. guidelines exist for HSCT for rheumatological disease treatment, but the European Society for Bone and Marrow Transplantation recommends autologous HSCT as part of clinical trials for the treatment of certain subgroups of patients with severe systemic sclerosis, systemic lupus and juvenile idiopathic arthritis.7

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
Explore This Issue
August 2017
Also By This Author
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

Ongoing Treatment Concerns

Although the therapy has a great deal of potential, many clinicians are concerned about the risk/benefit ratio. The conditioning regimen puts patients at risk of complications, such as infection, secondary autoimmune disease and malignancy.8 Some studies have shown an increase in short-term mortality following HSCT, but safety of HSCT has improved since its beginnings.8,9 Researchers continue to work to develop regimens that are effective, but less toxic.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Georges Georges, MD, is an associate member at Fred Hutchinson Cancer Research Center and an associate professor of medicine at the University of Washington, both in Seattle. He is part of a team that has performed such transplants in patients with severe autoimmune disease.

“There is always a com­petition between transplant and nontransplant therapy to find the most effective therapy that causes the least risk and discomfort. There is always the hope that there is some simpler drug therapy that can be developed [to] target specifically the cells responsible for the disease process.” He points out that this may be partly why research interest in HSCT has lessened for certain diseases that have more effective drug treatments, such as rheumatoid arthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patient Perspectives

Ms. Gould was diagnosed with systemic sclerosis in 2015. These photos show her hands and feet (left) prior to the transplant.

Ms. Gould was diagnosed with systemic sclerosis in 2015. These photos show her hands and feet (left) prior to the transplant.

What follows are perspectives from three women who received HSCT for disabling autoimmune conditions. All three received their treatment through Northwestern Feinberg School of Medicine’s Division of Immunotherapy for autoimmune disease.

HSCT & Lupus: Kathy Peel is a 36-year-old woman, a sales analyst, wife and mother of two. She was diagnosed with lupus in 2005.

Ms. Peel’s doctors had an extremely difficult time getting her disease under control, even with treatment. Her lung function had significantly deteriorated. Her doctor told her that she would never be able to come off prednisone and her disease would probably never go into remission.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Ms. Peel and her mother began researching alternatives. Ms. Peel says, “I found a YouTube video of a girl who had basically the same story and was in remission after HSCT. I connected with a group of people on Facebook who had either had the procedure or wanted to have it done, and I found out most of my information through them.”

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions Tagged With: Autoimmune, Biologics, Clinical, disease-modifying anti-rheumatic drugs, hematopoietic stem-cell transplantation, Juvenile idiopathic arthritis, Lupus, outcome, patient care, Research, Rheumatic Disease, Rheumatoid arthritis, rheumatology, Systemic sclerosis, TreatmentIssue: August 2017

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
  • Cellular Therapy of Autoimmune Disease

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.